A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases

Grant

Awarded By

Total Award Amount

  • 42864.00

    • Direct Costs

  • 31518.00

    • Sponsor Award Id

    • Contributor

  • Ahmed Elkhanany   Investigator  
  • Erica Stringer-Reasor M.D.   Principal Investigator  
  • Gabrielle Rocque M.D.   Investigator  
  • Katia Khoury   Investigator